NEXTHINK
28.10.2015 08:31:45 CET | Business Wire | Press release
Nexthink®, a pioneer and leader in end-user centric IT Operations Analytics (ITOA), today announced a partnership with Ymor , a leading APM service provider in the Netherlands. Under the agreement, Ymor will be able to provide consulting services, support and implement Nexthink’s IT analytics solutions for its customers.
Ymor unburdens customers through its Ketenbewaking™ service portfolio that protects and optimizes the IT environment by focusing on end-users. By integrating Nexthink’s technology into its offering, Ymor is able to expand and enhance its existing services. In addition to technical, configuration, end-to-end and component monitoring, Ymor can now offer its customers workspace monitoring. Nexthink’s visibility and IT analytics allow Ymor to provide control over the workspace that can lead to fast ROI and financial savings.
"As we strive for ‘end-user happiness,’ workplace monitoring is more important than ever before,” said Martin van den Berge, Director Ymor . “Throughout the workday, most end-users spend at least 5 hours using various applications. Performance issues cause frustration and lead to decreased efficiency for both end-users and the business. Working with Nexthink provides us with an opportunity to measure the end-user experience, to obtain a ‘helicopter view’ of the IT infrastructure, to quickly and easily find the root cause of issues and to achieve the goal of happy end-users.”
Ymor and Nexthink have implemented workplace monitoring with the city of The Hague. Gerard van Lieshout, Sr. Corporate IT Advisor of The Hague : “We use Nexthink to monitor all enterprise desktops, some 7,000 workspaces. By measuring delays, crashes and bottlenecks directly on the desktops, it gives us a better understanding on how our employees use the desktops. This not only allows us to respond better to reported incidents, but also to adjust configurations of the desktops before problems occur.”
“We are excited about the partnership with Ymor and extending our reach in Northern Europe,” said Nathan Wyld, Europe Channel Director at Nexthink . “As a result of this partnership, organisations in the Netherlands can benefit from Nexthink’s IT analytics and Ymor’s outstanding services and support for implementation and optimal use of IT analytics in their environments.”
###
About Ymor:
Ymor is a fast growing and innovative service provider based in Utrecht, which assists the Dutch Top 500 companies in improving the performance of complex IT environments with the goal of unburdening end-users. An organisation may be experiencing problems with performance or availability. It may be building a new application or wish to bring it online. Or there may simply be a need for the complex IT chain to be closely monitored. In all such cases the Ymor ‘Ketenbewaking’ service monitors and optimises the IT environment. Our slogan says it all: “Ymor creates user happiness!”
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028005061/en/
./ContentItem/FormatNexthink and Ymor partnership to meet demand for IT Analytics solutions in the Netherlands and significant customer win: city of The Hague
Contact:
Media contacts:
Nexthink
Victoria Calmon, +33 6
34 77 15 97
victoria.calmon@nexthink.com
www.nexthink.com
or
Ymor
Inge
Vollebregt, +31 610762591
ivollebregt@ymor.nl
www.ymor.nl
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
